Streetbeat News

Stock Prices

IMMP

Immutep has announced that its first-in-human Phase I study of IMP761 has been fully recruited and the drug has been administered without any safety issues.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:05 pm

RANI

Rani Therapeutics has released new preclinical data showing that their RaniPill platform can deliver a GLP-1 incretin triagonist orally, achieving rapid weight loss and bioavailability similar to injections. A Phase 1 study for RT-114 is expected in 2025.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:05 pm

PLRX

Pliant Therapeutics will present Phase 2a trial results of bexotegrast for primary sclerosing cholangitis at The Liver Meeting 2024. The data shows improvement in cholestasis markers and stabilization of liver fibrosis markers.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:01 pm

HST

In the past three months, 8 analysts have provided ratings for Host Hotels & Resorts (NASDAQ:HST), with a mix of bullish and indifferent perspectives. The average 12-month price target has decreased from $22.71 to $20.25. Analysts have adjusted their ratings and price targets in response to market conditions and company performance. Host Hotels & Resorts has shown strong financial performance with impressive revenue growth, net margin, ROE, and ROA, while maintaining a sound debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

October 17, 2024 | 12:00 pm

YOU

In the past three months, five analysts have rated Clear Secure (NYSE:YOU), with a majority being bullish. The average 12-month price target has increased by 5.14% to $36.8. Analysts have raised their price targets, reflecting positive sentiment. Clear Secure has shown strong financial performance with notable revenue growth and profitability, but faces higher financial risk due to a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

October 17, 2024 | 12:00 pm

NXL

Nexalin Technology, Inc (NASDAQ:NXL) announced positive results from a clinical trial of its Deep Intracranial Frequency Stimulation (DIFS) technology for mild Alzheimer's disease. The study showed improvements in memory and cognitive function, with significant gains in cognitive markers. The treatment was well-tolerated, indicating potential as a drug-free alternative or complement to existing treatments.

Portfolio Pulse from Anusuya Lahiri

October 17, 2024 | 12:00 pm

NXL

Nexalin Technology has announced promising results from a trial indicating that its DIFS technology increases neural activity and blood flow in the hippocampus, potentially offering a new treatment avenue for Alzheimer's disease.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:00 pm

JCI

Johnson Controls Intl (NYSE:JCI) has received 13 analyst ratings over the past three months, with a mix of bullish and bearish perspectives. The average 12-month price target has increased by 10.55% to $76.92. Analysts have raised their ratings and price targets, reflecting positive sentiment. Despite this, the company's financial metrics like net margin, ROE, and ROA lag behind industry averages, indicating potential challenges.

Portfolio Pulse from Benzinga Insights

October 17, 2024 | 12:00 pm

NXL

Nexalin Technology has announced a new study showing that its Deep Intracranial Frequency Stimulation (DIFS) significantly improves memory and cognitive function in Alzheimer's patients. This development could have positive implications for the company's future prospects.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:00 pm

DIS

Jim Cramer expressed interest in buying more shares of Disney if the stock price falls below $90, despite challenges in Disney's theme parks. Disney's experiences unit, including theme parks, now contributes significantly less to the company's income. The company plans a $60 billion investment in its experiences businesses over the next decade.

Portfolio Pulse from Benzinga Neuro

October 17, 2024 | 12:00 pm